Measuring the levels of the N‐terminal pro B-type natriuretic peptide (NT-proBNP) — a validated and widely accepted prognostic marker of pulmonary hypertension (PH) — in the urine of babies born prematurely is feasible, and may facilitate the screening of PH, a study suggests. The study, “Urinary NT-proBNP as…
Minimal incisions, shorter hospital stays, and faster recovery are some of the advantages of robotic heart surgery to repair a leaky mitral valve — a risk factor for pulmonary hypertension (PH) — compared to conventional open-heart surgery, says a cardiovascular surgeon at the Mayo Clinic. Patients with…
New York cardiopulmonary physical therapist Noah Greenspan has launched the Pulmonary Wellness Foundation (PWF), a nonprofit group that provides free online information on a range of prevalent, rare and ultra-rare pulmonary diseases for those who can’t afford to pay for it. PWF specifically targets patients with pulmonary fibrosis,…
Levels of a circular RNA molecule in the blood could help diagnose and predict the clinical outcomes of those with idiopathic pulmonary arterial hypertension (IPAH), a study suggests. The study, “Elevated serum circ_0068481 levels as a potential diagnostic and prognostic indicator in idiopathic pulmonary arterial hypertension,”…
Preliminary data from the Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) patients with heart failure and preserved ejection fraction (PH-HFpEF) showed that 86% of those analyzed responded to the therapy, with less pressure evident on heart’s left atrium. The ongoing trial’s predefined response criterion — the…
Orenitram (treprostinil tablets) reduced clinical worsening and slowed disease progression in people with pulmonary arterial hypertension (PAH) who had recently begun treatment with an alternative approved therapy, a Phase 3 clinical trial has found. Trial findings were reported in the study, “Combination Therapy with Oral Treprostinil for Pulmonary…
AI Therapeutics is seeking to advance the development of its candidate treatment LAM-001 for patients with lymphangioleiomyomatosis (LAM) and pulmonary arterial hypertension (PAH), two rare lung disorders. Specifically, the company is looking for a collaborator with commercial expertise to advance LAM-001 in a registrational trial for LAM…
An international consensus is lacking about what constitutes pulmonary hypertension (PH) in newborns, according to a review study, which recommends the use of standardized criteria to define the disease in these patients. The systematic review, “Variation in the definition of pulmonary hypertension and clinical indications for the use…
Acceleron Pharma and Fulcrum Therapeutics are working together to discover small molecules that can be used to treat pulmonary diseases, including pulmonary hypertension (PH). Under this collaboration, Acceleron will be able to access Fulcrum’s proprietary product engine and target identification platform, in order to identify small molecules…
Over the last year, Pulmonary Hypertension News has brought you the latest news about groundbreaking discoveries, treatment developments, clinical trials, and other events related to pulmonary hypertension (PH). As we look ahead to 2020, here are our top 10 most-read stories of 2019, with a summary of their significance for…
Bellerophon Therapeutics’ vasodilator INOpulse increased physical activity and improved quality of life in people with interstitial lung disease (PH-ILD) who are at risk of pulmonary hypertension, top-line results from a Phase 2/3 clinical trial show. These results are from the second group of patients taking part in…
Melatonin, a natural hormone involved in sleep and believed to protect against cardiovascular diseases, may help to relieve the signs and symptoms of pulmonary arterial hypertension (PAH), an early study in mice reports. In mice, melatonin protected lung blood vessels from damage, and inactivated proteins responsible for setting…
Get regular updates to your inbox.
